CSIMarket Company Name, Ticker, Suppliers, else..
 
Roivant Sciences Ltd   (NASDAQ: ROIV)
 
Price: $34.6400 $-0.07 -0.202%
Day's High: $35.34000015258789 Week Perf: -5.02 %
Day's Low: $ 34.01 30 Day Perf: 2.15 %
Volume (M): 39,066,033 52 Wk High: $ 38.00
Volume (M$): $ 0 52 Wk Avg: $25.82
Open: $34.65 52 Wk Low: $11.94



 Market Capitalization (Millions $) 24,035
 Shares Outstanding (Millions) 694
 Employees 750
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -398
 Cash Flow (TTM) (Millions $) -1,295
 Capital Exp. (TTM) (Millions $) 13

Business Description


Roivant Sciences Ltd is a biopharmaceutical company that focuses on developing innovative therapeutics for various diseases and conditions. The company's goal is to rapidly bring treatments to patients by leveraging emerging technologies and data-driven approaches. Roivant Sciences operates through subsidiary companies, known as Vants, each dedicated to a specific therapeutic area or technology platform. These Vants conduct research and development, clinical trials, and commercialization efforts for their respective areas. Roivant Sciences aims to address unmet medical needs and improve patient outcomes by bringing new and effective therapies to market.


   Company Address: 7th Floor London 0 NY
   Company Phone Number: 400 3347   Stock Exchange / Ticker: NASDAQ ROIV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
KYNB   -2.51%    
PFE        1.75% 
RCUS   -2.79%    
SPRO        0.41% 
SXTP      0% 
TCRT   -1.16%    
• View Complete Report
   



Clinical Study

Immunovants Batoclimab Shows Promising Six-Month Remission Data, Potentially Transforming Management of Uncontrolled...

Published Thu, Sep 4 2025 3:40 AM UTC

In a significant development for the management of uncontrolled Graves disease (GD), Immunovant, Inc. has released pivotal data concerning its investigational therapy, batoclimab. The findings, which will be formally presented at the upcoming Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025, indicate that patients treated with batoclimab experi...
Clinical Study

Emerging Therapeutics in Autoimmunity Batoclimab Demonstrates Promising Efficacy in Myasthenia Gravis, Chronic Inflam...

Published Wed, Mar 19 2025 12:00 PM UTC

The field of immunology continues to evolve with promising advancements in therapeutic options for autoimmune diseases. A noteworthy development is the emergence of batoclimab, an investigational fully human IgG1 monoclonal antibody targeting the neonatal Fc receptor (FcRn). This innovative therapeutic has recently shown positive results across multiple autoimmune conditi...
Shares

Roivant Sciences Reshapes Arbutus Biopharmas Governance Amidst Market Volatility and Strategic Acquisitions in the Biopharmaceutical Sector

Published Tue, Feb 25 2025 1:00 PM UTC

In a significant move within the biopharmaceutical landscape, Roivant Sciences Ltd. announced on February 25, 2025, a notable reshuffle in the Board of Directors of Arbutus Biopharma Corporation. All former Board members have resigned, and Roivant has taken control of the governance of Arbutus, a company in which it holds a substantial stake of 38,847,462 common shares, repr...
Merger and Acquisition

Roivant Sciences VTAMA Cream Approved for Plaque Psoriasis, Eyes Atopic Dermatitis Indication as FDA Review Looms

Published Wed, Sep 18 2024 11:30 AM UTC

Breaking News: Roivant Sciences Innovative VTAMA Cream Gains Approval for Plaque Psoriasis Treatment; FDA Review for Atopic Dermatitis UnderwaySeptember 10, 2024 - In a significant advancement for psoriasis management, Roivant Sciences Ltd. (NASDAQ: ROIV) has announced that the FDA has approved its newly developed VTAMA cream, a non-steroidal topical therapy designed specif...
Clinical Study

Revolutionizing Care Pulmovants Groundbreaking Inhaled Treatments and Immunovants Advances in Autoimmune Di...

Published Tue, Sep 10 2024 10:30 AM UTC

In a landscape where medical advancements are critical for combating respiratory and autoimmune diseases, Pulmovant and its sister company, Immunovant, recently showcased promising innovations. Yesterday, at the European Respiratory Society (ERS) Congress in Vienna, Austria, Pulmovant presented compelling proof-of-concept data from the Phase 1b ATMOS study of its inhaled sol...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2,909.86
Price to Sales (Expected) -
Price to Book 4.54
PEG (TTM) -

Financial Strength Current
Quick Ratio 15.26
Working Capital Ratio 18.37
Leverage Ratio (MRQ) 0.22
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.55 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) -
Cash 6.19 $
Book Value 7.63 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 11,013
Net Income per Employee (TTM) -530,543
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) 16477.78 %
Net Margin (MRQ) 14116.83 %
Net Cash Flow Margin (MRQ) -2293.17 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Roivant Sciences Ltd's Segments
Reportable Segment    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.